Should You Quit Your Job for a Startup? The Psychology of Startups vs Corporations Through the Barbarians to Bureaucrats Framework Most people answer that question by looking at compensation, titles, equity, prestige, or company size. I think they are asking the wrong question. This solo episode I explores the Barbarians to Bureaucrats framework and why career success often depends on matching your psychology to the stage of the organization you are helping build. I discuss why some professionals thrive in ambiguity while others excel in structured environments, why startups and corporations require completely different operating styles, how organizational mass influences decision making, and why understanding where you belong on the curve can transform the trajectory of your career. The goal is not deciding whether startups are better than corporations.The goal is understanding where you perform at your highest level. For operators, founders, executives, and ambitious professionals, this conversation offers a practical framework for making better career decisions and finding the environment where you can create your greatest impact. Episode Breakdown 00:00 Why Your Next Career Move Might Be Wrong 00:01 Intro The Career Question Everyone Asks 02:00 Barbarians to Bureaucrats Framework Explained 04:15 Corporate Life Cycles and Personality Fit 06:35 Prophet, Barbarian, Builder, and Bureaucrat 08:45 Why Some People Thrive in Startups 11:10 The Physics of Company Growth 13:40 Why Large Companies Move Slower 16:05 Process vs Innovation 18:20 Startup Chaos vs Corporate Structure 20:30 Are You a Startup Person or a Corporate Person? 22:15 Why Bureaucracy Exists 23:50 The Biggest Career Mistake Professionals Make 25:10 Finding the Right Stage of Company Growth 26:30 How to Evaluate Your Next Opportunity 27:45 The Intuitive Surgical Lesson 28:35 Where Do You Belong on the Curve? 29:00 Final Thoughts on Career Growth

How Category Leaders Engineer Markets and Capture Outsized Value. Most companies focus on building products.Category leaders focus on building markets. Bruce Cleveland, Chief Executive Officer of Traction Gap Partners, sat down with me for a deep discussion on market engineering, category creation, thought leadership, and the strategic disciplines that separate market leaders from market participants. We explored why category leaders capture a disproportionate share of industry value, how companies engineer demand before scaling sales, why thought leadership should be driven by the CEO, and why product innovation alone rarely creates sustainable market leadership. One of the most important ideas from the conversation is simple. Markets do not build themselves. The companies that shape categories, define the rules, and influence how buyers think often create significantly more value than the companies focused solely on product execution. For founders, investors, operators, and executives, this episode provides actionable insights on shaping demand, establishing category leadership, and creating lasting competitive advantage. Episode Breakdown: 00:00 The $1.3 Billion Mistake and Lessons From Silicon Valley 01:54 Intro Bruce Cleveland's Background 04:37 @Oracle , @Apple , and Siebel Systems 08:50 Building Category-Defining Companies 12:35 Why Most Startups Fail 15:49 Market Problems vs Sales Problems 18:54 The Story Behind Traction Gap 22:26 Why Bruce Wrote Market Engineering 23:48 What is Market Engineering? 27:26 The Five Pillars of Market Engineering 30:45 Category Design, Messaging, and Storytelling 34:41 Why Great Products Still Fail 36:31 Market Engineering vs Demand Generation 39:27 Early Signals That a Market Is Forming 42:00 Why Market Engineering is the CEO's Job 44:59 Thought Leadership in MedTech 46:18 The Three Core Market Engineering Artifacts 49:04 Building a Category Others Want to Join 52:40 Category Leadership and Competitive Advantage 54:27 Why Early Adopters Matter 57:12 Creating a Single Source of Truth 01:00:20 AI, Search, and the Future of Market Visibility 01:03:50 AI-Powered Market Engineering Tools 01:06:46 Aligning Teams Around a Market Strategy 01:09:15 Final Thoughts on Market Leadership 01:11:00 Outro

Why Most Go-To-Market Strategies Fail in the AI Era and What Apollo.io’s CEO Says Elite Companies Do Differently Most companies still chase growth through more campaigns, more sales hires, and more software layered onto broken systems. I sat down with Matt Curl, Chief Executive Officer at Apollo.io, for a sharp conversation on why modern go to market strategy now depends on unified execution across sales, marketing, operations, customer intelligence, automation, and AI native workflows. Matt breaks down how Apollo.io scaled into one of the leading AI native go to market platforms while explaining why durable market leadership rarely comes from product strength alone. Distribution, positioning, execution speed, and customer understanding increasingly determine which companies dominate categories. The conversation also explores account based marketing, AI driven personalization, MedTech commercialization, physician adoption behavior, and why elite companies shape market perception before competitors fully recognize the shift happening around them. One of the strongest insights from the episode focuses on how AI amplifies operational strengths and weaknesses at the same time. Fragmented systems create faster chaos. Strategic alignment creates faster growth.Exceptional companies no longer treat go to market as isolated activity. They build intelligent commercial systems designed to compound execution, positioning, customer intelligence, and revenue growth at scale. Episode Breakdown: 00:00 Why the First 10 Sales Don’t Matter 00:40 Intro Matt Curl, CEO of Apollo.io 02:01 What Apollo Does and Why It Matters 03:14 What is Go-To-Market (GTM)? 05:18 The Four Pillars of Modern GTM 08:25 Why Only a Few Thousand Companies Do GTM Well 09:50 COVID, AI, and the Evolution of GTM 11:01 Why the Best Product Doesn't Always Win 13:10 Market Engineering vs Sales Problems 16:25 Why Data is the Oxygen of GTM 18:00 Simple Data Signals That Improve Conversion 19:28 Advanced Data Intelligence Explained 21:18 Category, Messaging, Narrative, and GTM 22:06 Product-Market Fit vs Messaging Failures 24:53 AI and the Future of Personalized GTM 28:01 Apollo’s Category and Market Positioning 30:04 ABM Explained the Right Way 31:42 MedTech, Early Adopters, and Market Selection 34:43 Why Messaging Determines Adoption 36:18 Product-Market Fit vs Market-Product Fit 39:21 How to Find Early Adopters 41:48 What MedTech Gets Wrong About GTM 44:42 Why Relationships Aren’t a Scalable Moat 45:54 The Difference Between 10 Sales and 10,000 Sales 46:36 Why AI Can’t Fix Broken Fundamentals 48:59 The Real Metric That Matters 50:46 The One Trait Shared by Great GTM Teams 51:57 Who Should Own Go-To-Market? 53:18 Why Data-Driven Leaders Win 54:22 Building a Unified GTM System 56:10 Why Winning Customers Creates Winning Companies 58:05 Final GTM Advice for Founders and CEOs 59:29 Outro

How Category Leaders Engineer Markets and Capture Outsized Value. Most companies focus on building products.Category leaders focus on building markets. Bruce Cleveland, Chief Executive Officer of Traction Gap Partners, sat down with me for a deep discussion on market engineering, category creation, thought leadership, and the strategic disciplines that separate market leaders from market participants. We explored why category leaders capture a disproportionate share of industry value, how companies engineer demand before scaling sales, why thought leadership should be driven by the CEO, and why product innovation alone rarely creates sustainable market leadership. One of the most important ideas from the conversation is simple. Markets do not build themselves. The companies that shape categories, define the rules, and influence how buyers think often create significantly more value than the companies focused solely on product execution. For founders, investors, operators, and executives, this episode provides actionable insights on shaping demand, establishing category leadership, and creating lasting competitive advantage. Episode Breakdown: 00:00 The $1.3 Billion Mistake and Lessons From Silicon Valley 01:54 Intro Bruce Cleveland's Background 04:37 @Oracle , @Apple , and Siebel Systems 08:50 Building Category-Defining Companies 12:35 Why Most Startups Fail 15:49 Market Problems vs Sales Problems 18:54 The Story Behind Traction Gap 22:26 Why Bruce Wrote Market Engineering 23:48 What is Market Engineering? 27:26 The Five Pillars of Market Engineering 30:45 Category Design, Messaging, and Storytelling 34:41 Why Great Products Still Fail 36:31 Market Engineering vs Demand Generation 39:27 Early Signals That a Market Is Forming 42:00 Why Market Engineering is the CEO's Job 44:59 Thought Leadership in MedTech 46:18 The Three Core Market Engineering Artifacts 49:04 Building a Category Others Want to Join 52:40 Category Leadership and Competitive Advantage 54:27 Why Early Adopters Matter 57:12 Creating a Single Source of Truth 01:00:20 AI, Search, and the Future of Market Visibility 01:03:50 AI-Powered Market Engineering Tools 01:06:46 Aligning Teams Around a Market Strategy 01:09:15 Final Thoughts on Market Leadership 01:11:00 Outro

Why Most Go-To-Market Strategies Fail in the AI Era and What Apollo.io’s CEO Says Elite Companies Do Differently Most companies still chase growth through more campaigns, more sales hires, and more software layered onto broken systems. I sat down with Matt Curl, Chief Executive Officer at Apollo.io, for a sharp conversation on why modern go to market strategy now depends on unified execution across sales, marketing, operations, customer intelligence, automation, and AI native workflows. Matt breaks down how Apollo.io scaled into one of the leading AI native go to market platforms while explaining why durable market leadership rarely comes from product strength alone. Distribution, positioning, execution speed, and customer understanding increasingly determine which companies dominate categories. The conversation also explores account based marketing, AI driven personalization, MedTech commercialization, physician adoption behavior, and why elite companies shape market perception before competitors fully recognize the shift happening around them. One of the strongest insights from the episode focuses on how AI amplifies operational strengths and weaknesses at the same time. Fragmented systems create faster chaos. Strategic alignment creates faster growth.Exceptional companies no longer treat go to market as isolated activity. They build intelligent commercial systems designed to compound execution, positioning, customer intelligence, and revenue growth at scale. Episode Breakdown: 00:00 Why the First 10 Sales Don’t Matter 00:40 Intro Matt Curl, CEO of Apollo.io 02:01 What Apollo Does and Why It Matters 03:14 What is Go-To-Market (GTM)? 05:18 The Four Pillars of Modern GTM 08:25 Why Only a Few Thousand Companies Do GTM Well 09:50 COVID, AI, and the Evolution of GTM 11:01 Why the Best Product Doesn't Always Win 13:10 Market Engineering vs Sales Problems 16:25 Why Data is the Oxygen of GTM 18:00 Simple Data Signals That Improve Conversion 19:28 Advanced Data Intelligence Explained 21:18 Category, Messaging, Narrative, and GTM 22:06 Product-Market Fit vs Messaging Failures 24:53 AI and the Future of Personalized GTM 28:01 Apollo’s Category and Market Positioning 30:04 ABM Explained the Right Way 31:42 MedTech, Early Adopters, and Market Selection 34:43 Why Messaging Determines Adoption 36:18 Product-Market Fit vs Market-Product Fit 39:21 How to Find Early Adopters 41:48 What MedTech Gets Wrong About GTM 44:42 Why Relationships Aren’t a Scalable Moat 45:54 The Difference Between 10 Sales and 10,000 Sales 46:36 Why AI Can’t Fix Broken Fundamentals 48:59 The Real Metric That Matters 50:46 The One Trait Shared by Great GTM Teams 51:57 Who Should Own Go-To-Market? 53:18 Why Data-Driven Leaders Win 54:22 Building a Unified GTM System 56:10 Why Winning Customers Creates Winning Companies 58:05 Final GTM Advice for Founders and CEOs 59:29 Outro

This Month in MedTech: Boston Scientific’s $1.5B Bet and the Rise of Focused Strategics. Nicholas Talamantes, Sr. Director at (@lsintelligence) Life Science Intelligence, joined me for a deep dive into Q1 earnings, MedTech M&A, strategic focus, and the market signals shaping the next phase of healthcare innovation. We covered (@bostonsci) Boston Scientific’s $1.5B structural heart bet, the rise of focused strategics, J&J’s Atraverse acquisition, Medtronic’s renewed deal activity, Roche’s expansion into AI-powered pathology, ResMed’s move beyond sleep apnea, and the growing use of option-based deal structures across MedTech. One of the clearest themes from the episode is that focus is being rewarded. Companies with concentrated portfolios are delivering stronger growth, while larger platforms continue divesting, acquiring, and repositioning around their highest-value opportunities. The conversation also explores why commercial proof is becoming the most important trigger for acquisitions, how strategics are approaching risk differently, and what recent earnings reveal about the future direction of MedTech. For founders, investors, operators, and healthcare leaders, this episode offers a sharp look at where capital, competition, innovation, and market momentum are moving next. Episode Breakdown 00:00 Why Focused MedTech Companies Are Winning 00:02 Intro This Month in MedTech 02:03 Q1 Earnings Overview and Market Trends 03:54 AI Hype vs Healthcare Revenue Reality 05:40 What Q1 Earnings Tell Us About MedTech 07:36 Why Focus Beats Diversification 08:55 Edwards Lifesciences' Strong Quarter 10:14 Intuitive Surgical's Growth Engine 11:01 Insulet’s 34% Growth Story 12:52 Why Insulet’s Stock Fell Anyway 16:52 Lessons From Public Market Reactions 18:25 @bostonsci Boston Scientific’s Mixed Quarter 21:22 Stryker’s Cyberattack and Growth Outlook 23:39 @Medtronic's Return to Aggressive M&A 24:53 J&J’s Cardiovascular Growth Strategy 25:39 Abbott’s Cardiovascular Momentum 26:12 Why Cardiovascular Is Dominating MedTech 29:01 Key Takeaways From Q1 Earnings 30:43 Boston Scientific’s $1.5B Structural Heart Bet 31:48 Boston’s Third Attempt at TAVR 34:18 What Makes the Mirus Valve Different? 36:24 Minority Stakes vs Full Acquisitions 37:47 J&J Acquires Atraverse Medical 39:20 The Team Behind Farapulse Strikes Again 41:08 Why Repeat Founders Matter in MedTech 43:20 @AtraverseInc Atraverse Clinical Results Explained 44:57 Where EP Innovation Is Heading Next 47:53 Is MedTech Entering an M&A Boom? 48:53 ResMed Acquires Noctrix Health 49:40 Artivion Buys Endospan 50:34 Roche Acquires PathAI 51:43 Medtronic Acquires SPR Therapeutics 53:17 M&A Trends and Strategic Optionality 55:38 Why More Acquisitions May Be Coming 57:58 The Rise of Option-Based Deal Structures 01:00:35 Speed Round: Notable Funding Deals 01:01:00 Butterfly Medical $21M Series C 01:02:27 SonoMind $23.5M Series A 01:03:45 Aidoc Raises $150M 01:05:30 Illuminant Surgical $8.4M Seed 01:08:06 Perimeter Medical $10.5M Financing 01:10:15 AI, Cancer Care, and Clinical Impact 01:13:05 Biggest Lessons From May 2026 01:17:10 Final Thoughts on Focus, Growth, and M&A 01:22:00 Outro

How Category Leaders Engineer Markets and Capture Outsized Value. Most companies focus on building products.Category leaders focus on building markets. Bruce Cleveland, Chief Executive Officer of Traction Gap Partners, sat down with me for a deep discussion on market engineering, category creation, thought leadership, and the strategic disciplines that separate market leaders from market participants. We explored why category leaders capture a disproportionate share of industry value, how companies engineer demand before scaling sales, why thought leadership should be driven by the CEO, and why product innovation alone rarely creates sustainable market leadership. One of the most important ideas from the conversation is simple. Markets do not build themselves. The companies that shape categories, define the rules, and influence how buyers think often create significantly more value than the companies focused solely on product execution. For founders, investors, operators, and executives, this episode provides actionable insights on shaping demand, establishing category leadership, and creating lasting competitive advantage. Episode Breakdown: 00:00 The $1.3 Billion Mistake and Lessons From Silicon Valley 01:54 Intro Bruce Cleveland's Background 04:37 @Oracle , @Apple , and Siebel Systems 08:50 Building Category-Defining Companies 12:35 Why Most Startups Fail 15:49 Market Problems vs Sales Problems 18:54 The Story Behind Traction Gap 22:26 Why Bruce Wrote Market Engineering 23:48 What is Market Engineering? 27:26 The Five Pillars of Market Engineering 30:45 Category Design, Messaging, and Storytelling 34:41 Why Great Products Still Fail 36:31 Market Engineering vs Demand Generation 39:27 Early Signals That a Market Is Forming 42:00 Why Market Engineering is the CEO's Job 44:59 Thought Leadership in MedTech 46:18 The Three Core Market Engineering Artifacts 49:04 Building a Category Others Want to Join 52:40 Category Leadership and Competitive Advantage 54:27 Why Early Adopters Matter 57:12 Creating a Single Source of Truth 01:00:20 AI, Search, and the Future of Market Visibility 01:03:50 AI-Powered Market Engineering Tools 01:06:46 Aligning Teams Around a Market Strategy 01:09:15 Final Thoughts on Market Leadership 01:11:00 Outro

Should You Quit Your Job for a Startup? The Psychology of Startups vs Corporations Through the Barbarians to Bureaucrats Framework Most people answer that question by looking at compensation, titles, equity, prestige, or company size. I think they are asking the wrong question. This solo episode I explores the Barbarians to Bureaucrats framework and why career success often depends on matching your psychology to the stage of the organization you are helping build. I discuss why some professionals thrive in ambiguity while others excel in structured environments, why startups and corporations require completely different operating styles, how organizational mass influences decision making, and why understanding where you belong on the curve can transform the trajectory of your career. The goal is not deciding whether startups are better than corporations.The goal is understanding where you perform at your highest level. For operators, founders, executives, and ambitious professionals, this conversation offers a practical framework for making better career decisions and finding the environment where you can create your greatest impact. Episode Breakdown 00:00 Why Your Next Career Move Might Be Wrong 00:01 Intro The Career Question Everyone Asks 02:00 Barbarians to Bureaucrats Framework Explained 04:15 Corporate Life Cycles and Personality Fit 06:35 Prophet, Barbarian, Builder, and Bureaucrat 08:45 Why Some People Thrive in Startups 11:10 The Physics of Company Growth 13:40 Why Large Companies Move Slower 16:05 Process vs Innovation 18:20 Startup Chaos vs Corporate Structure 20:30 Are You a Startup Person or a Corporate Person? 22:15 Why Bureaucracy Exists 23:50 The Biggest Career Mistake Professionals Make 25:10 Finding the Right Stage of Company Growth 26:30 How to Evaluate Your Next Opportunity 27:45 The Intuitive Surgical Lesson 28:35 Where Do You Belong on the Curve? 29:00 Final Thoughts on Career Growth

Should You Quit Your Job for a Startup? The Psychology of Startups vs Corporations Through the Barbarians to Bureaucrats Framework Most people answer that question by looking at compensation, titles, equity, prestige, or company size. I think they are asking the wrong question. This solo episode I explores the Barbarians to Bureaucrats framework and why career success often depends on matching your psychology to the stage of the organization you are helping build. I discuss why some professionals thrive in ambiguity while others excel in structured environments, why startups and corporations require completely different operating styles, how organizational mass influences decision making, and why understanding where you belong on the curve can transform the trajectory of your career. The goal is not deciding whether startups are better than corporations.The goal is understanding where you perform at your highest level. For operators, founders, executives, and ambitious professionals, this conversation offers a practical framework for making better career decisions and finding the environment where you can create your greatest impact. Episode Breakdown 00:00 Why Your Next Career Move Might Be Wrong 00:01 Intro The Career Question Everyone Asks 02:00 Barbarians to Bureaucrats Framework Explained 04:15 Corporate Life Cycles and Personality Fit 06:35 Prophet, Barbarian, Builder, and Bureaucrat 08:45 Why Some People Thrive in Startups 11:10 The Physics of Company Growth 13:40 Why Large Companies Move Slower 16:05 Process vs Innovation 18:20 Startup Chaos vs Corporate Structure 20:30 Are You a Startup Person or a Corporate Person? 22:15 Why Bureaucracy Exists 23:50 The Biggest Career Mistake Professionals Make 25:10 Finding the Right Stage of Company Growth 26:30 How to Evaluate Your Next Opportunity 27:45 The Intuitive Surgical Lesson 28:35 Where Do You Belong on the Curve? 29:00 Final Thoughts on Career Growth

How the Elephant Slide Helps Healthtech and MedTech Leaders Create Better Board Meetings, Stronger Investor Alignment, and Clearer Strategic Direction. Most MedTech board meetings overload people with updates but fail to explain what the updates actually mean. I recently broke down the Elephant Slide framework and why I believe it is one of the most important communication tools a MedTech CEO can learn. The conversation explores why clinical milestones, financing, commercialization, regulatory timelines, and cash runway cannot be discussed separately in MedTech. Everything is connected. A trial delay changes financing conversations. Commercial traction shapes investor confidence. Market belief impacts adoption long before scale happens. I also discuss why investor anxiety often comes from missing context instead of bad news itself, and why the strongest CEOs control narrative before the boardroom starts building its own version of the story. One of the biggest leadership lessons from this episode is simple:Great CEOs do not just present information. They bring investors, operators, and board members onto the same page around what matters most. For founders, investors, operators, and MedTech leaders, this is a sharp conversation on boardroom strategy, fundraising psychology, commercialization, and narrative control inside complex healthcare companies. Episode Breakdown 00:00 Why Board Meetings Go Wrong 00:36 What is an Elephant Slide? 00:57 Intro Why This Matters for CEOs 01:13 Why You Should Watch This Episode 01:14 The Origin of the Elephant Slide 02:30 Why Most Board Decks Fail 04:00 The Real Problem in Board Meetings 05:40 Why CEOs Must Control the Narrative 06:30 The Blind Men and the Elephant Story 08:10 Why Board Members Get Confused 09:25 The Fictional “Neo” MedTech Example 10:15 Why Data Alone Creates Anxiety 11:17 What Board Members Are Really Thinking 14:32 The “Bottom Line First” Framework 16:00 Why Context Matters More Than Updates 17:30 How Enrollment Delays Affect Financing 18:45 Market Engineering and Board Communication 20:00 Why FDA Clearance Isn’t Enough 21:00 The Most Important Slide in Every Board Deck 22:10 Strategy vs Operations vs Housekeeping 23:00 Why Great CEOs Control the Narrative 23:58 Final Advice for Your Next Board Meeting 24:40 Outro Subscribe 25:18 End

How Category Leaders Engineer Markets and Capture Outsized Value. Most companies focus on building products.Category leaders focus on building markets. Bruce Cleveland, Chief Executive Officer of Traction Gap Partners, sat down with me for a deep discussion on market engineering, category creation, thought leadership, and the strategic disciplines that separate market leaders from market participants. We explored why category leaders capture a disproportionate share of industry value, how companies engineer demand before scaling sales, why thought leadership should be driven by the CEO, and why product innovation alone rarely creates sustainable market leadership. One of the most important ideas from the conversation is simple. Markets do not build themselves. The companies that shape categories, define the rules, and influence how buyers think often create significantly more value than the companies focused solely on product execution. For founders, investors, operators, and executives, this episode provides actionable insights on shaping demand, establishing category leadership, and creating lasting competitive advantage. Episode Breakdown: 00:00 The $1.3 Billion Mistake and Lessons From Silicon Valley 01:54 Intro Bruce Cleveland's Background 04:37 @Oracle , @Apple , and Siebel Systems 08:50 Building Category-Defining Companies 12:35 Why Most Startups Fail 15:49 Market Problems vs Sales Problems 18:54 The Story Behind Traction Gap 22:26 Why Bruce Wrote Market Engineering 23:48 What is Market Engineering? 27:26 The Five Pillars of Market Engineering 30:45 Category Design, Messaging, and Storytelling 34:41 Why Great Products Still Fail 36:31 Market Engineering vs Demand Generation 39:27 Early Signals That a Market Is Forming 42:00 Why Market Engineering is the CEO's Job 44:59 Thought Leadership in MedTech 46:18 The Three Core Market Engineering Artifacts 49:04 Building a Category Others Want to Join 52:40 Category Leadership and Competitive Advantage 54:27 Why Early Adopters Matter 57:12 Creating a Single Source of Truth 01:00:20 AI, Search, and the Future of Market Visibility 01:03:50 AI-Powered Market Engineering Tools 01:06:46 Aligning Teams Around a Market Strategy 01:09:15 Final Thoughts on Market Leadership 01:11:00 Outro

Why Most Go-To-Market Strategies Fail in the AI Era and What Apollo.io’s CEO Says Elite Companies Do Differently Most companies still chase growth through more campaigns, more sales hires, and more software layered onto broken systems. I sat down with Matt Curl, Chief Executive Officer at Apollo.io, for a sharp conversation on why modern go to market strategy now depends on unified execution across sales, marketing, operations, customer intelligence, automation, and AI native workflows. Matt breaks down how Apollo.io scaled into one of the leading AI native go to market platforms while explaining why durable market leadership rarely comes from product strength alone. Distribution, positioning, execution speed, and customer understanding increasingly determine which companies dominate categories. The conversation also explores account based marketing, AI driven personalization, MedTech commercialization, physician adoption behavior, and why elite companies shape market perception before competitors fully recognize the shift happening around them. One of the strongest insights from the episode focuses on how AI amplifies operational strengths and weaknesses at the same time. Fragmented systems create faster chaos. Strategic alignment creates faster growth.Exceptional companies no longer treat go to market as isolated activity. They build intelligent commercial systems designed to compound execution, positioning, customer intelligence, and revenue growth at scale. Episode Breakdown: 00:00 Why the First 10 Sales Don’t Matter 00:40 Intro Matt Curl, CEO of Apollo.io 02:01 What Apollo Does and Why It Matters 03:14 What is Go-To-Market (GTM)? 05:18 The Four Pillars of Modern GTM 08:25 Why Only a Few Thousand Companies Do GTM Well 09:50 COVID, AI, and the Evolution of GTM 11:01 Why the Best Product Doesn't Always Win 13:10 Market Engineering vs Sales Problems 16:25 Why Data is the Oxygen of GTM 18:00 Simple Data Signals That Improve Conversion 19:28 Advanced Data Intelligence Explained 21:18 Category, Messaging, Narrative, and GTM 22:06 Product-Market Fit vs Messaging Failures 24:53 AI and the Future of Personalized GTM 28:01 Apollo’s Category and Market Positioning 30:04 ABM Explained the Right Way 31:42 MedTech, Early Adopters, and Market Selection 34:43 Why Messaging Determines Adoption 36:18 Product-Market Fit vs Market-Product Fit 39:21 How to Find Early Adopters 41:48 What MedTech Gets Wrong About GTM 44:42 Why Relationships Aren’t a Scalable Moat 45:54 The Difference Between 10 Sales and 10,000 Sales 46:36 Why AI Can’t Fix Broken Fundamentals 48:59 The Real Metric That Matters 50:46 The One Trait Shared by Great GTM Teams 51:57 Who Should Own Go-To-Market? 53:18 Why Data-Driven Leaders Win 54:22 Building a Unified GTM System 56:10 Why Winning Customers Creates Winning Companies 58:05 Final GTM Advice for Founders and CEOs 59:29 Outro

This Month in MedTech: Boston Scientific’s $1.5B Bet and the Rise of Focused Strategics. Nicholas Talamantes, Sr. Director at (@lsintelligence) Life Science Intelligence, joined me for a deep dive into Q1 earnings, MedTech M&A, strategic focus, and the market signals shaping the next phase of healthcare innovation. We covered (@bostonsci) Boston Scientific’s $1.5B structural heart bet, the rise of focused strategics, J&J’s Atraverse acquisition, Medtronic’s renewed deal activity, Roche’s expansion into AI-powered pathology, ResMed’s move beyond sleep apnea, and the growing use of option-based deal structures across MedTech. One of the clearest themes from the episode is that focus is being rewarded. Companies with concentrated portfolios are delivering stronger growth, while larger platforms continue divesting, acquiring, and repositioning around their highest-value opportunities. The conversation also explores why commercial proof is becoming the most important trigger for acquisitions, how strategics are approaching risk differently, and what recent earnings reveal about the future direction of MedTech. For founders, investors, operators, and healthcare leaders, this episode offers a sharp look at where capital, competition, innovation, and market momentum are moving next. Episode Breakdown 00:00 Why Focused MedTech Companies Are Winning 00:02 Intro This Month in MedTech 02:03 Q1 Earnings Overview and Market Trends 03:54 AI Hype vs Healthcare Revenue Reality 05:40 What Q1 Earnings Tell Us About MedTech 07:36 Why Focus Beats Diversification 08:55 Edwards Lifesciences' Strong Quarter 10:14 Intuitive Surgical's Growth Engine 11:01 Insulet’s 34% Growth Story 12:52 Why Insulet’s Stock Fell Anyway 16:52 Lessons From Public Market Reactions 18:25 @bostonsci Boston Scientific’s Mixed Quarter 21:22 Stryker’s Cyberattack and Growth Outlook 23:39 @Medtronic's Return to Aggressive M&A 24:53 J&J’s Cardiovascular Growth Strategy 25:39 Abbott’s Cardiovascular Momentum 26:12 Why Cardiovascular Is Dominating MedTech 29:01 Key Takeaways From Q1 Earnings 30:43 Boston Scientific’s $1.5B Structural Heart Bet 31:48 Boston’s Third Attempt at TAVR 34:18 What Makes the Mirus Valve Different? 36:24 Minority Stakes vs Full Acquisitions 37:47 J&J Acquires Atraverse Medical 39:20 The Team Behind Farapulse Strikes Again 41:08 Why Repeat Founders Matter in MedTech 43:20 @AtraverseInc Atraverse Clinical Results Explained 44:57 Where EP Innovation Is Heading Next 47:53 Is MedTech Entering an M&A Boom? 48:53 ResMed Acquires Noctrix Health 49:40 Artivion Buys Endospan 50:34 Roche Acquires PathAI 51:43 Medtronic Acquires SPR Therapeutics 53:17 M&A Trends and Strategic Optionality 55:38 Why More Acquisitions May Be Coming 57:58 The Rise of Option-Based Deal Structures 01:00:35 Speed Round: Notable Funding Deals 01:01:00 Butterfly Medical $21M Series C 01:02:27 SonoMind $23.5M Series A 01:03:45 Aidoc Raises $150M 01:05:30 Illuminant Surgical $8.4M Seed 01:08:06 Perimeter Medical $10.5M Financing 01:10:15 AI, Cancer Care, and Clinical Impact 01:13:05 Biggest Lessons From May 2026 01:17:10 Final Thoughts on Focus, Growth, and M&A 01:22:00 Outro

Why Most Go-To-Market Strategies Fail in the AI Era and What Apollo.io’s CEO Says Elite Companies Do Differently Most companies still chase growth through more campaigns, more sales hires, and more software layered onto broken systems. I sat down with Matt Curl, Chief Executive Officer at Apollo.io, for a sharp conversation on why modern go to market strategy now depends on unified execution across sales, marketing, operations, customer intelligence, automation, and AI native workflows. Matt breaks down how Apollo.io scaled into one of the leading AI native go to market platforms while explaining why durable market leadership rarely comes from product strength alone. Distribution, positioning, execution speed, and customer understanding increasingly determine which companies dominate categories. The conversation also explores account based marketing, AI driven personalization, MedTech commercialization, physician adoption behavior, and why elite companies shape market perception before competitors fully recognize the shift happening around them. One of the strongest insights from the episode focuses on how AI amplifies operational strengths and weaknesses at the same time. Fragmented systems create faster chaos. Strategic alignment creates faster growth.Exceptional companies no longer treat go to market as isolated activity. They build intelligent commercial systems designed to compound execution, positioning, customer intelligence, and revenue growth at scale. Episode Breakdown: 00:00 Why the First 10 Sales Don’t Matter 00:40 Intro Matt Curl, CEO of Apollo.io 02:01 What Apollo Does and Why It Matters 03:14 What is Go-To-Market (GTM)? 05:18 The Four Pillars of Modern GTM 08:25 Why Only a Few Thousand Companies Do GTM Well 09:50 COVID, AI, and the Evolution of GTM 11:01 Why the Best Product Doesn't Always Win 13:10 Market Engineering vs Sales Problems 16:25 Why Data is the Oxygen of GTM 18:00 Simple Data Signals That Improve Conversion 19:28 Advanced Data Intelligence Explained 21:18 Category, Messaging, Narrative, and GTM 22:06 Product-Market Fit vs Messaging Failures 24:53 AI and the Future of Personalized GTM 28:01 Apollo’s Category and Market Positioning 30:04 ABM Explained the Right Way 31:42 MedTech, Early Adopters, and Market Selection 34:43 Why Messaging Determines Adoption 36:18 Product-Market Fit vs Market-Product Fit 39:21 How to Find Early Adopters 41:48 What MedTech Gets Wrong About GTM 44:42 Why Relationships Aren’t a Scalable Moat 45:54 The Difference Between 10 Sales and 10,000 Sales 46:36 Why AI Can’t Fix Broken Fundamentals 48:59 The Real Metric That Matters 50:46 The One Trait Shared by Great GTM Teams 51:57 Who Should Own Go-To-Market? 53:18 Why Data-Driven Leaders Win 54:22 Building a Unified GTM System 56:10 Why Winning Customers Creates Winning Companies 58:05 Final GTM Advice for Founders and CEOs 59:29 Outro

How the Elephant Slide Helps Healthtech and MedTech Leaders Create Better Board Meetings, Stronger Investor Alignment, and Clearer Strategic Direction. Most MedTech board meetings overload people with updates but fail to explain what the updates actually mean. I recently broke down the Elephant Slide framework and why I believe it is one of the most important communication tools a MedTech CEO can learn. The conversation explores why clinical milestones, financing, commercialization, regulatory timelines, and cash runway cannot be discussed separately in MedTech. Everything is connected. A trial delay changes financing conversations. Commercial traction shapes investor confidence. Market belief impacts adoption long before scale happens. I also discuss why investor anxiety often comes from missing context instead of bad news itself, and why the strongest CEOs control narrative before the boardroom starts building its own version of the story. One of the biggest leadership lessons from this episode is simple:Great CEOs do not just present information. They bring investors, operators, and board members onto the same page around what matters most. For founders, investors, operators, and MedTech leaders, this is a sharp conversation on boardroom strategy, fundraising psychology, commercialization, and narrative control inside complex healthcare companies. Episode Breakdown 00:00 Why Board Meetings Go Wrong 00:36 What is an Elephant Slide? 00:57 Intro Why This Matters for CEOs 01:13 Why You Should Watch This Episode 01:14 The Origin of the Elephant Slide 02:30 Why Most Board Decks Fail 04:00 The Real Problem in Board Meetings 05:40 Why CEOs Must Control the Narrative 06:30 The Blind Men and the Elephant Story 08:10 Why Board Members Get Confused 09:25 The Fictional “Neo” MedTech Example 10:15 Why Data Alone Creates Anxiety 11:17 What Board Members Are Really Thinking 14:32 The “Bottom Line First” Framework 16:00 Why Context Matters More Than Updates 17:30 How Enrollment Delays Affect Financing 18:45 Market Engineering and Board Communication 20:00 Why FDA Clearance Isn’t Enough 21:00 The Most Important Slide in Every Board Deck 22:10 Strategy vs Operations vs Housekeeping 23:00 Why Great CEOs Control the Narrative 23:58 Final Advice for Your Next Board Meeting 24:40 Outro Subscribe 25:18 End

This Month in MedTech: Boston Scientific’s $1.5B Bet and the Rise of Focused Strategics. Nicholas Talamantes, Sr. Director at (@lsintelligence) Life Science Intelligence, joined me for a deep dive into Q1 earnings, MedTech M&A, strategic focus, and the market signals shaping the next phase of healthcare innovation. We covered (@bostonsci) Boston Scientific’s $1.5B structural heart bet, the rise of focused strategics, J&J’s Atraverse acquisition, Medtronic’s renewed deal activity, Roche’s expansion into AI-powered pathology, ResMed’s move beyond sleep apnea, and the growing use of option-based deal structures across MedTech. One of the clearest themes from the episode is that focus is being rewarded. Companies with concentrated portfolios are delivering stronger growth, while larger platforms continue divesting, acquiring, and repositioning around their highest-value opportunities. The conversation also explores why commercial proof is becoming the most important trigger for acquisitions, how strategics are approaching risk differently, and what recent earnings reveal about the future direction of MedTech. For founders, investors, operators, and healthcare leaders, this episode offers a sharp look at where capital, competition, innovation, and market momentum are moving next. Episode Breakdown 00:00 Why Focused MedTech Companies Are Winning 00:02 Intro This Month in MedTech 02:03 Q1 Earnings Overview and Market Trends 03:54 AI Hype vs Healthcare Revenue Reality 05:40 What Q1 Earnings Tell Us About MedTech 07:36 Why Focus Beats Diversification 08:55 Edwards Lifesciences' Strong Quarter 10:14 Intuitive Surgical's Growth Engine 11:01 Insulet’s 34% Growth Story 12:52 Why Insulet’s Stock Fell Anyway 16:52 Lessons From Public Market Reactions 18:25 @bostonsci Boston Scientific’s Mixed Quarter 21:22 Stryker’s Cyberattack and Growth Outlook 23:39 @Medtronic's Return to Aggressive M&A 24:53 J&J’s Cardiovascular Growth Strategy 25:39 Abbott’s Cardiovascular Momentum 26:12 Why Cardiovascular Is Dominating MedTech 29:01 Key Takeaways From Q1 Earnings 30:43 Boston Scientific’s $1.5B Structural Heart Bet 31:48 Boston’s Third Attempt at TAVR 34:18 What Makes the Mirus Valve Different? 36:24 Minority Stakes vs Full Acquisitions 37:47 J&J Acquires Atraverse Medical 39:20 The Team Behind Farapulse Strikes Again 41:08 Why Repeat Founders Matter in MedTech 43:20 @AtraverseInc Atraverse Clinical Results Explained 44:57 Where EP Innovation Is Heading Next 47:53 Is MedTech Entering an M&A Boom? 48:53 ResMed Acquires Noctrix Health 49:40 Artivion Buys Endospan 50:34 Roche Acquires PathAI 51:43 Medtronic Acquires SPR Therapeutics 53:17 M&A Trends and Strategic Optionality 55:38 Why More Acquisitions May Be Coming 57:58 The Rise of Option-Based Deal Structures 01:00:35 Speed Round: Notable Funding Deals 01:01:00 Butterfly Medical $21M Series C 01:02:27 SonoMind $23.5M Series A 01:03:45 Aidoc Raises $150M 01:05:30 Illuminant Surgical $8.4M Seed 01:08:06 Perimeter Medical $10.5M Financing 01:10:15 AI, Cancer Care, and Clinical Impact 01:13:05 Biggest Lessons From May 2026 01:17:10 Final Thoughts on Focus, Growth, and M&A 01:22:00 Outro

This Month in MedTech: Boston Scientific’s $1.5B Bet and the Rise of Focused Strategics. Nicholas Talamantes, Sr. Director at (@lsintelligence) Life Science Intelligence, joined me for a deep dive into Q1 earnings, MedTech M&A, strategic focus, and the market signals shaping the next phase of healthcare innovation. We covered (@bostonsci) Boston Scientific’s $1.5B structural heart bet, the rise of focused strategics, J&J’s Atraverse acquisition, Medtronic’s renewed deal activity, Roche’s expansion into AI-powered pathology, ResMed’s move beyond sleep apnea, and the growing use of option-based deal structures across MedTech. One of the clearest themes from the episode is that focus is being rewarded. Companies with concentrated portfolios are delivering stronger growth, while larger platforms continue divesting, acquiring, and repositioning around their highest-value opportunities. The conversation also explores why commercial proof is becoming the most important trigger for acquisitions, how strategics are approaching risk differently, and what recent earnings reveal about the future direction of MedTech. For founders, investors, operators, and healthcare leaders, this episode offers a sharp look at where capital, competition, innovation, and market momentum are moving next. Episode Breakdown 00:00 Why Focused MedTech Companies Are Winning 00:02 Intro This Month in MedTech 02:03 Q1 Earnings Overview and Market Trends 03:54 AI Hype vs Healthcare Revenue Reality 05:40 What Q1 Earnings Tell Us About MedTech 07:36 Why Focus Beats Diversification 08:55 Edwards Lifesciences' Strong Quarter 10:14 Intuitive Surgical's Growth Engine 11:01 Insulet’s 34% Growth Story 12:52 Why Insulet’s Stock Fell Anyway 16:52 Lessons From Public Market Reactions 18:25 @bostonsci Boston Scientific’s Mixed Quarter 21:22 Stryker’s Cyberattack and Growth Outlook 23:39 @Medtronic's Return to Aggressive M&A 24:53 J&J’s Cardiovascular Growth Strategy 25:39 Abbott’s Cardiovascular Momentum 26:12 Why Cardiovascular Is Dominating MedTech 29:01 Key Takeaways From Q1 Earnings 30:43 Boston Scientific’s $1.5B Structural Heart Bet 31:48 Boston’s Third Attempt at TAVR 34:18 What Makes the Mirus Valve Different? 36:24 Minority Stakes vs Full Acquisitions 37:47 J&J Acquires Atraverse Medical 39:20 The Team Behind Farapulse Strikes Again 41:08 Why Repeat Founders Matter in MedTech 43:20 @AtraverseInc Atraverse Clinical Results Explained 44:57 Where EP Innovation Is Heading Next 47:53 Is MedTech Entering an M&A Boom? 48:53 ResMed Acquires Noctrix Health 49:40 Artivion Buys Endospan 50:34 Roche Acquires PathAI 51:43 Medtronic Acquires SPR Therapeutics 53:17 M&A Trends and Strategic Optionality 55:38 Why More Acquisitions May Be Coming 57:58 The Rise of Option-Based Deal Structures 01:00:35 Speed Round: Notable Funding Deals 01:01:00 Butterfly Medical $21M Series C 01:02:27 SonoMind $23.5M Series A 01:03:45 Aidoc Raises $150M 01:05:30 Illuminant Surgical $8.4M Seed 01:08:06 Perimeter Medical $10.5M Financing 01:10:15 AI, Cancer Care, and Clinical Impact 01:13:05 Biggest Lessons From May 2026 01:17:10 Final Thoughts on Focus, Growth, and M&A 01:22:00 Outro

The Book of Elon: Exploring Elon Musk’s Most Useful Ideas with Author Eric Jorgenson. In this episode, Omar Khateeb welcomes @EricJorgenson, CEO at @scribemediaco and author of The Book of Elon, for a deep conversation on ideas, authorship, and innovation. Eric discusses how he curated (@elonmusk) Elon Musk’s most important thinking into a book designed to help founders, engineers, and builders better understand first principles thinking and mission driven leadership. They also explore the evolving role of publishing, why timeless ideas deserve better curation, and how books can become intellectual assets that shape industries. For founders, creators, and thinkers interested in the intersection of entrepreneurship and writing, this episode offers valuable insight into how powerful ideas become lasting books. Episode Breakdown: 00:00 Introduction and Why Focus Matters More Than Time 01:42 The Real Problem Founders Face 04:10 First Principles Thinking Explained 07:28 How Elon Musk Approaches Problems Differently 10:52 Why Most People Work on the Wrong Things 14:20 The Power of Clarity in Decision Making 17:05 Turning Ideas Into Actionable Systems 20:12 What Separates Builders From Thinkers 23:40 Writing as a Tool for Clear Thinking 27:18 How The Book of Elon Was Created 30:05 Curating Ideas That Actually Matter 33:22 Why Most Content Lacks Depth 36:40 The Role of Mission Driven Thinking 40:15 How Great Founders Stay Focused 43:30 The Tradeoff Between Speed and Quality 47:05 Lessons From Elon Musk’s Execution Style 50:28 Why Constraints Create Better Outcomes 54:10 The Importance of Long Term Thinking 57:42 Building Products That Actually Matter 01:01:10 Advice for Founders and Builders 01:04:35 The Future of Publishing and Ideas 01:08:00 How to Think Better and Build Smarter 01:11:20 Final Thoughts and Key Takeaways

This Month in MedTech: Boston Scientific’s $1.5B Bet and the Rise of Focused Strategics. Nicholas Talamantes, Sr. Director at (@lsintelligence) Life Science Intelligence, joined me for a deep dive into Q1 earnings, MedTech M&A, strategic focus, and the market signals shaping the next phase of healthcare innovation. We covered (@bostonsci) Boston Scientific’s $1.5B structural heart bet, the rise of focused strategics, J&J’s Atraverse acquisition, Medtronic’s renewed deal activity, Roche’s expansion into AI-powered pathology, ResMed’s move beyond sleep apnea, and the growing use of option-based deal structures across MedTech. One of the clearest themes from the episode is that focus is being rewarded. Companies with concentrated portfolios are delivering stronger growth, while larger platforms continue divesting, acquiring, and repositioning around their highest-value opportunities. The conversation also explores why commercial proof is becoming the most important trigger for acquisitions, how strategics are approaching risk differently, and what recent earnings reveal about the future direction of MedTech. For founders, investors, operators, and healthcare leaders, this episode offers a sharp look at where capital, competition, innovation, and market momentum are moving next. Episode Breakdown 00:00 Why Focused MedTech Companies Are Winning 00:02 Intro This Month in MedTech 02:03 Q1 Earnings Overview and Market Trends 03:54 AI Hype vs Healthcare Revenue Reality 05:40 What Q1 Earnings Tell Us About MedTech 07:36 Why Focus Beats Diversification 08:55 Edwards Lifesciences' Strong Quarter 10:14 Intuitive Surgical's Growth Engine 11:01 Insulet’s 34% Growth Story 12:52 Why Insulet’s Stock Fell Anyway 16:52 Lessons From Public Market Reactions 18:25 @bostonsci Boston Scientific’s Mixed Quarter 21:22 Stryker’s Cyberattack and Growth Outlook 23:39 @Medtronic's Return to Aggressive M&A 24:53 J&J’s Cardiovascular Growth Strategy 25:39 Abbott’s Cardiovascular Momentum 26:12 Why Cardiovascular Is Dominating MedTech 29:01 Key Takeaways From Q1 Earnings 30:43 Boston Scientific’s $1.5B Structural Heart Bet 31:48 Boston’s Third Attempt at TAVR 34:18 What Makes the Mirus Valve Different? 36:24 Minority Stakes vs Full Acquisitions 37:47 J&J Acquires Atraverse Medical 39:20 The Team Behind Farapulse Strikes Again 41:08 Why Repeat Founders Matter in MedTech 43:20 @AtraverseInc Atraverse Clinical Results Explained 44:57 Where EP Innovation Is Heading Next 47:53 Is MedTech Entering an M&A Boom? 48:53 ResMed Acquires Noctrix Health 49:40 Artivion Buys Endospan 50:34 Roche Acquires PathAI 51:43 Medtronic Acquires SPR Therapeutics 53:17 M&A Trends and Strategic Optionality 55:38 Why More Acquisitions May Be Coming 57:58 The Rise of Option-Based Deal Structures 01:00:35 Speed Round: Notable Funding Deals 01:01:00 Butterfly Medical $21M Series C 01:02:27 SonoMind $23.5M Series A 01:03:45 Aidoc Raises $150M 01:05:30 Illuminant Surgical $8.4M Seed 01:08:06 Perimeter Medical $10.5M Financing 01:10:15 AI, Cancer Care, and Clinical Impact 01:13:05 Biggest Lessons From May 2026 01:17:10 Final Thoughts on Focus, Growth, and M&A 01:22:00 Outro

Why Most Go-To-Market Strategies Fail in the AI Era and What Apollo.io’s CEO Says Elite Companies Do Differently Most companies still chase growth through more campaigns, more sales hires, and more software layered onto broken systems. I sat down with Matt Curl, Chief Executive Officer at Apollo.io, for a sharp conversation on why modern go to market strategy now depends on unified execution across sales, marketing, operations, customer intelligence, automation, and AI native workflows. Matt breaks down how Apollo.io scaled into one of the leading AI native go to market platforms while explaining why durable market leadership rarely comes from product strength alone. Distribution, positioning, execution speed, and customer understanding increasingly determine which companies dominate categories. The conversation also explores account based marketing, AI driven personalization, MedTech commercialization, physician adoption behavior, and why elite companies shape market perception before competitors fully recognize the shift happening around them. One of the strongest insights from the episode focuses on how AI amplifies operational strengths and weaknesses at the same time. Fragmented systems create faster chaos. Strategic alignment creates faster growth.Exceptional companies no longer treat go to market as isolated activity. They build intelligent commercial systems designed to compound execution, positioning, customer intelligence, and revenue growth at scale. Episode Breakdown: 00:00 Why the First 10 Sales Don’t Matter 00:40 Intro Matt Curl, CEO of Apollo.io 02:01 What Apollo Does and Why It Matters 03:14 What is Go-To-Market (GTM)? 05:18 The Four Pillars of Modern GTM 08:25 Why Only a Few Thousand Companies Do GTM Well 09:50 COVID, AI, and the Evolution of GTM 11:01 Why the Best Product Doesn't Always Win 13:10 Market Engineering vs Sales Problems 16:25 Why Data is the Oxygen of GTM 18:00 Simple Data Signals That Improve Conversion 19:28 Advanced Data Intelligence Explained 21:18 Category, Messaging, Narrative, and GTM 22:06 Product-Market Fit vs Messaging Failures 24:53 AI and the Future of Personalized GTM 28:01 Apollo’s Category and Market Positioning 30:04 ABM Explained the Right Way 31:42 MedTech, Early Adopters, and Market Selection 34:43 Why Messaging Determines Adoption 36:18 Product-Market Fit vs Market-Product Fit 39:21 How to Find Early Adopters 41:48 What MedTech Gets Wrong About GTM 44:42 Why Relationships Aren’t a Scalable Moat 45:54 The Difference Between 10 Sales and 10,000 Sales 46:36 Why AI Can’t Fix Broken Fundamentals 48:59 The Real Metric That Matters 50:46 The One Trait Shared by Great GTM Teams 51:57 Who Should Own Go-To-Market? 53:18 Why Data-Driven Leaders Win 54:22 Building a Unified GTM System 56:10 Why Winning Customers Creates Winning Companies 58:05 Final GTM Advice for Founders and CEOs 59:29 Outro